Retina Group of New England

What Retina Group of New England does

Retina Group of New England (RGNE) is a physician-owned ophthalmology practice specializing in the diagnosis and treatment of retinal, vitreous, and macular diseases. Founded in 1999, the practice operates across four Connecticut locations (Waterford, Norwich, Guilford, and Wethersfield) and serves patients throughout southeastern Connecticut and Rhode Island. The clinical team comprises four fellowship-trained vitreoretinal surgeons and the practice operates as one of the larger ophthalmic clinical research centers in the two-state region.

RGNE generates revenue primarily through fee-for-service clinical care — including intravitreal anti-VEGF injections, retinal surgery, and diagnostic imaging — supplemented by clinical trial principal investigator fees from pharmaceutical sponsors. The practice has served as a principal investigator site for trials supporting FDA approval of major ophthalmic drugs including Lucentis, Eylea, Vabysmo, Syfovre, Susvimo, Izervay, and Eylea HD, and was the first site in Connecticut for two gene therapy AMD trials. Diagnostic and treatment platforms include Heidelberg Spectralis, Optos P200Tx, and LumiThera photobiomodulation. Go-to-market is driven by referrals from community optometrists and ophthalmologists, supplemented by self-referring patients seeking subspecialty retinal care.

As a physician-owned practice without private equity or venture backing, RGNE funds expansion through operating cash flow from clinical collections and clinical research contracts. The practice is positioned in a high-demand subspecialty given the aging demographic of its New England catchment and the rising prevalence of age-related macular degeneration, diabetic retinopathy, and other retinal conditions requiring sustained in-person care.

Name

Retina Group of New England

Legal name

Retina Group of New England

Website

https://retinagroupofnewengland.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Retina Group of New England is a physician-owned ophthalmology practice operating four Connecticut locations, specializing in retinal, vitreous, and macular disease treatment delivered by four fellowship-trained vitreoretinal surgeons serving southeastern CT and Rhode Island.

Ownership category

akta.pro rank

Product category

Specialty Ophthalmology / Vitreoretinal Care

NAICS

Offices of Physicians (62111), Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Retina & Vitreous Specialists (HLAKAKAE)

akta.pro secondary industries

Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN), Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB), Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades) (HLAHAJAJ)

Keywords

• Retinal disease treatment
• Vitreoretinal surgery
• Ophthalmic diagnostic imaging
• Age-related macular degeneration
• Clinical research trials

Headquarters

HQ city

Waterford

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Patient Care Services: Revenue generated from providing ophthalmic/retinal medical services to patients at four Connecticut locations, including examinations, diagnostic imaging, in-office treatments (intravitreal injections, laser procedures, cryotherapy), and vitreoretinal surgery. Operates standard medical practice billing with insurance (Medicare, etc.). Patients pay copays/deductibles at time of service.
2. Clinical Research Trials: The practice conducts numerous clinical trials for retinal diseases (wet AMD, dry AMD, diabetic macular edema, retinal vein occlusions) as one of the largest ophthalmic research centers in CT and RI. Participation in trials may generate research funding, investigator fees, and early access to novel therapies.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Retina Group of New England is a private subspecialty ophthalmology practice providing medical, surgical, and clinical research services for diseases of the retina, vitreous, and macula. The practice delivers diagnostic imaging (OCT, OCT-A, fluorescein angiography, wide-field imaging, ICG angiography, ocular ultrasound), in-office treatments (intravitreal injections, laser photocoagulation, cryotherapy, photobiomodulation), and vitreoretinal surgery (vitrectomy, pneumatic retinopexy) across four Connecticut locations, supported by an active clinical trials program for AMD, diabetic macular edema, and retinal vein occlusions.

Product overview

Retina Group of New England is a medical practice offering specialized ophthalmological and vitreoretinal care services. The practice operates as a single, unified healthcare delivery organization with four Connecticut locations (Guilford, Norwich, Waterford, and Wethersfield). The core offering consists of diagnostic imaging services (OCT, OCT-A, fluorescein angiography, wide-field imaging, ICG angiography, and ocular ultrasound), in-office treatments (intravitreal injections, laser photocoagulation, cryotherapy, photobiomodulation), and surgical procedures (vitrectomy, pneumatic retinopexy). Supporting services include a patient portal for medical records access and online bill pay, as well as an active clinical research program conducting trials for macular degeneration, diabetic retinopathy, and retinal vein occlusion treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Retina Group of New England Medical Practice Comprehensive medical and surgical care for diseases of the retina, vitreous, and macula, including age-related macular degeneration, diabetic retinopathy, retinal detachment, retinal vein occlusions, macular holes, epiretinal membranes, uveitis, hereditary retinal diseases, ocular trauma, intraocular tumors, and cataract surgery complications. For patients in Connecticut and Rhode Island.
• Diagnostic Imaging Services Comprehensive diagnostic imaging including Optical Coherence Tomography (OCT), OCT-Angiography, Fluorescein Angiography, Wide-Field Retinal Imaging, ICG Angiography, and Ocular Ultrasound (B-Scan) for detailed examination of retinal conditions. For patients with suspected or diagnosed retinal disease.
• In-Office Treatments In-office retinal treatments including Intravitreal Injections, LumiThera Photobiomodulation (for dry AMD), Laser Photocoagulation, and Cryotherapy for various retinal conditions. For patients requiring procedural retinal care without surgery.
• Vitreoretinal Surgery Surgical procedures including vitrectomy for retinal detachment repair, macular hole treatment, epiretinal membrane removal, and pneumatic retinopexy. For patients with surgical retinal conditions.
• Clinical Research Program Active clinical trials program conducting research for treatments of wet and dry macular degeneration, diabetic macular edema, and retinal vein occlusions. For patients eligible for sponsored clinical trials and referring physicians.
• Patient Portal and Online Bill Pay Online patient portal (MyPatientVisit) for accessing medical records, scheduling appointments, online payments without login, and bilingual (English/Spanish) patient communications. For patients of the practice.

Quantifiable outcome

• In-office pneumatic retinopexy achieves 75% success rate for retinal detachment treatment without outpatient surgery.
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Mid Atlantic Retina: Vitreoretinal specialty group operating across multiple locations in the Mid-Atlantic; same subspecialty focus, in-office imaging and injection suite model, and high clinical trial activity in AMD/DME/RVO.
• Vitreoretinal Consultants: Fellowship-trained vitreoretinal surgeon group practice; directly comparable in service mix (imaging, intravitreal injections, vitrectomy surgery, clinical research) and patient referral dynamics.
• New England Retina Associates: Regional vitreoretinal specialty practice in the New England area; directly comparable multi-physician retinal group focused on the same disease conditions (AMD, diabetic retinopathy, retinal detachment) and serving an overlapping patient referral base.
• Retina Associates of Cleveland: Multi-physician vitreoretinal specialty practice; comparable operating model with fellowship-trained retinal surgeons, in-office imaging and injection capabilities, surgical services, and active clinical trial participation in the same therapeutic indications.
• Retina Consultants of Texas / RCOA-affiliated groups: Large multi-site vitreoretinal specialty practice network with active clinical trial programs and same retinal indications (AMD, DME, RVO); same physician-owned group model with research-driven growth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/retinagroupofnewengland
• LinkedInlinkedin.com/company/retina-group-of-new-england-p.c

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Retina Group of New England